Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N‐terminal pro‐brain natriuretic peptide

Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and... INTRODUCTIONHeart failure (HF) is a pivotal public health issue which influences over 5.7 million American people and takes $37.2 billion every year and its morbidity reaches epidemic proportions. Moreover, it is evaluated that 45% of women and 59% of men die in 5 years after a HF diagnosis. Chronic HF (CHF) is a long‐term product of heart failure, is usually managed by treating symptoms and patients suffering from deteriorating symptoms and signs may need hospitalization or more frequent doctor visits. The most common causes of HF are as follow: coronary artery disease, high blood pressure, atrial fibrillation, previous myocardial infarction (heart attack), valvular heart disease, cardiomyopathy, infection, and excessive alcohol consumption. The prevalence and occurrence of HF progressively increases with age, with the most affected age group being over 50 years. In developed countries, 1%‐2% of the adult population suffers from HF, increasing to ≥10% for those older than 70 years. The National Institute for Health and Care Excellence (NICE) recommends measurement of brain natriuretic peptide combined with an ultrasound of the heart in the occurrence of symptom development. Up until now no elite diagnostic criterion has been established for HF.Suppression of tumorigenicity 2 (ST2), namely an interleukin (IL)‐33 related receptor, is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Laboratory Analysis Wiley

Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N‐terminal pro‐brain natriuretic peptide

Loading next page...
 
/lp/wiley/diagnosis-of-chronic-heart-failure-by-the-soluble-suppression-of-XGWiTPtT0H
Publisher
Wiley
Copyright
Copyright © 2018 Wiley Periodicals, Inc.
ISSN
0887-8013
eISSN
1098-2825
D.O.I.
10.1002/jcla.22295
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHeart failure (HF) is a pivotal public health issue which influences over 5.7 million American people and takes $37.2 billion every year and its morbidity reaches epidemic proportions. Moreover, it is evaluated that 45% of women and 59% of men die in 5 years after a HF diagnosis. Chronic HF (CHF) is a long‐term product of heart failure, is usually managed by treating symptoms and patients suffering from deteriorating symptoms and signs may need hospitalization or more frequent doctor visits. The most common causes of HF are as follow: coronary artery disease, high blood pressure, atrial fibrillation, previous myocardial infarction (heart attack), valvular heart disease, cardiomyopathy, infection, and excessive alcohol consumption. The prevalence and occurrence of HF progressively increases with age, with the most affected age group being over 50 years. In developed countries, 1%‐2% of the adult population suffers from HF, increasing to ≥10% for those older than 70 years. The National Institute for Health and Care Excellence (NICE) recommends measurement of brain natriuretic peptide combined with an ultrasound of the heart in the occurrence of symptom development. Up until now no elite diagnostic criterion has been established for HF.Suppression of tumorigenicity 2 (ST2), namely an interleukin (IL)‐33 related receptor, is

Journal

Journal of Clinical Laboratory AnalysisWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off